
Aramark (ARMK) Stock Forecast & Price Target
Aramark (ARMK) Analyst Ratings
Bulls say
Aramark reported a total revenue increase of 6% year-over-year, exceeding consensus estimates and aligning with the company's full-year growth guidance, which is projected between 7-9%. The company demonstrated notable growth within its segments, with FSS International rising 17% year-over-year, while maintaining solid performance in FSS USA. Additionally, Aramark's advancements in internal supply chain efficiencies through AI and successful execution in key markets reflect a robust turnaround and position the company for further market share gains in the healthcare sector.
Bears say
Aramark’s stock has faced consistent underperformance since its return to the public markets in 2013, highlighted by sluggish revenue generation compared to industry peers, with only 18% derived from high-margin segments versus 39% and 47% for Compass and Sodexo, respectively. The company is currently challenged by extended timelines to achieve financial goals, disappointing margin performance, and pressures from weakened consumer spending, particularly in sensitive sectors such as sports, leisure, and hospitality. Furthermore, operational issues, a lack of progress on debt reduction, and rising costs due to inflation contribute to a negative outlook as skepticism regarding Aramark's ability to achieve its fiscal targets persists.
This aggregate rating is based on analysts' research of Aramark and is not a guaranteed prediction by Public.com or investment advice.
Aramark (ARMK) Analyst Forecast & Price Prediction
Start investing in Aramark (ARMK)
Order type
Buy in
Order amount
Est. shares
0 shares